CHARLES SCHWAB INVESTMENT MANAGEMENT INC - PARATEK PHARMACEUTICALS INC ownership

PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 111 filers reported holding PARATEK PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of PARATEK PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$38,465
-13.0%
17,4050.0%0.00%
Q1 2023$44,209
+35.8%
17,4050.0%0.00%
Q4 2022$32,547
-27.7%
17,4050.0%0.00%
Q3 2022$45,000
+32.4%
17,4050.0%0.00%
Q2 2022$34,000
-91.2%
17,405
-86.6%
0.00%
Q1 2022$386,000
-29.9%
129,672
+5.7%
0.00%
Q4 2021$551,000
-2.7%
122,653
+5.4%
0.00%
Q3 2021$566,000
-72.6%
116,342
-61.6%
0.00%
-100.0%
Q2 2021$2,065,000
+6.5%
302,670
+10.2%
0.00%0.0%
Q1 2021$1,939,000
+14.1%
274,540
+1.1%
0.00%0.0%
Q4 2020$1,700,000
+17.5%
271,478
+1.6%
0.00%0.0%
Q3 2020$1,447,000
+5.9%
267,332
+2.2%
0.00%0.0%
Q2 2020$1,366,000
+92.1%
261,654
+16.0%
0.00%
Q1 2020$711,000
-12.3%
225,597
+12.2%
0.00%
Q4 2019$811,000
-2.8%
201,028
+4.2%
0.00%
Q3 2019$834,000
+25.4%
192,883
+15.9%
0.00%
Q2 2019$665,000
-16.9%
166,448
+11.6%
0.00%
-100.0%
Q1 2019$800,000
-1.1%
149,192
-5.3%
0.00%0.0%
Q4 2018$809,000
-47.7%
157,535
-1.2%
0.00%0.0%
Q3 2018$1,548,000
+8.3%
159,527
+13.8%
0.00%0.0%
Q2 2018$1,430,000
-14.6%
140,130
+8.8%
0.00%0.0%
Q1 2018$1,674,000
+1.2%
128,746
+39.4%
0.00%0.0%
Q4 2017$1,654,000
-19.8%
92,366
+12.4%
0.00%
-50.0%
Q3 2017$2,063,000
+133.6%
82,164
+124.4%
0.00%
+100.0%
Q2 2017$883,000
+82.4%
36,608
+45.8%
0.00%
Q1 2017$484,000
+25.1%
25,1080.0%0.00%
Q4 2016$387,000
+18.3%
25,1080.0%0.00%
Q3 2016$327,000
-6.6%
25,1080.0%0.00%
Q2 2016$350,000
+32.1%
25,108
+44.2%
0.00%
Q1 2016$265,000
-19.9%
17,4080.0%0.00%
Q4 2015$331,0000.0%17,4080.0%0.00%
Q3 2015$331,000
-26.3%
17,4080.0%0.00%
-100.0%
Q2 2015$449,00017,4080.00%
Other shareholders

There were no reported owners of PARATEK PHARMACEUTICALS INC in Q4 2020.

NameSharesValueWeighting ↓
View complete list of PARATEK PHARMACEUTICALS INC shareholders